December 21, 2020 by Chain Drug Review
diabetes, Lisa Hines, Pharmacy Quality Alliance (PQA)
Leading Headlines, Pharmacy

ALEXANDRIA, Va. – The Pharmacy Quality Alliance (PQA), through a majority vote of its members, has endorsed two new health plan performance measures. The measures evaluate medications to treat individuals with diabetes. More than 34 million Americans have diabetes, according to the Centers for Disease Control and Prevention. These measures will help evaluate the quality of
October 13, 2020 by Chain Drug Review
diabetes, GlucoDown Diabetic Friendly Tea Mix is sugar-free and decaffeinated, Walmart
Leading Headlines, Retail News, Supplier News

BENTONVILLE, Ark.— Soon it will be much easier and more convenient to buy GlucoDown at Walmart. Beginning this month, in-store availability of GlucoDown Diabetic Friendly Peach Tea Mix is expanding to more than 2000 Walmart pharmacies for 2021 – more GlucoDown at more Walmart pharmacies nationwide than ever before. Walmart has stocked GlucoDown Diabetic Friendly Peach
August 31, 2020 by Chain Drug Review
Biocon Biologics India Ltd, diabetes, mylan, Mylan CEO Heather Bresch, Mylan president Rajiv Malik
Leading Headlines, Supplier News

PITTSBURGH— Mylan N.V. and Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., announced on Monday the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not
July 27, 2020 by Chain Drug Review
diabetes, Laura Cranston, PQA
Leading Headlines, Pharmacy

ALEXANDRIA, Va. – Humana, Pfizer and Walgreens are collaborating with the Pharmacy Quality Alliance (PQA) to evaluate the impact of pharmacist-provided care on medication use, health and economic outcomes in patients with diabetes. The project brings together national leaders in pharmacy, care delivery, medications, and health plan administration to demonstrate the value of collaboration between
November 18, 2019 by Scott Howell
diabetes, Echosens, liver diseases, Scott Howell
Issue 11-18-2019, Pharmacy

A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH). The main risk factors for fatty liver disease include a sedentary
September 23, 2019 by Pooyan Kazemian
Department of Medicine at Harvard Medical School, diabetes, Pooyan Kazemian
Issue 09-23-2019, Opinion, Pharmacy

Adults with diabetes have a two- to three-times increased risk of early death compared to individuals without diabetes. Leaving diabetes uncontrolled can damage the kidneys, eyes, nerves and heart. Our new study published in JAMA Internal Medicine found that less than one in four American adults diagnosed with diabetes reach the care targets recommended by
June 6, 2019 by Chain Drug Review
diabetes
Issue 06-03-2019
Pharmacy accounts for the vast majority of chain drug store sales, and diabetes care is among the larger contributors to pharmacy volume. But the category is not without challenges. Most recently, insulin price inflation has raised a barrier to the purchase of — and adherence to — this life-saving prescription. The issue led Democratic and
March 18, 2019 by Dr. Juan Frias
American Liver Foundation, diabetes, Nonalcoholic fatty liver disease (NAFLD)
Issue 03-18-2019, Pharmacy

The American Liver Foundation estimates that over 30% of the U.S. population has some degree of nonalcoholic fatty liver disease (NAFLD), the most common type of liver disease in the Western world. This can impact other facets of their overall health, because NAFLD has been linked to diabetes, obesity, insulin resistance and other metabolic risk
March 18, 2019 by Dave Chase
diabetes, insulin
Issue 03-18-2019, Pharmacy

Last month, one furloughed government worker made national headlines by saying she had to ration her insulin because she couldn’t afford her co-pay, nor the ER bill, during the government shutdown. Recalling a day where her blood sugar was high, she admitted, “I just went to bed and hoped I’d wake up.” This is not
August 13, 2018 by Tina Moen
diabetes, IBM Watson Health, Sugar.IQ app, Tina Moen
Pharmacy, Technology

NEW YORK — The pharmacist plays an essential role in the continuum of care for many patients and is central to health care. While many patients might not realize it, a visit to the pharmacy is likely their most frequent opportunity to interact with a health care professional. Pharmacists are the most accessible health care
July 16, 2018 by Chain Drug Review
diabetes, Medicare, NACDS, pharmacists
Leading Headlines, Pharmacy

ARLINGTON, Va. – A National Association of Chain Drug Stores ) op-ed published by Morning Consult today describes the role of community pharmacy practice and of NACDS members’ philanthropic initiatives in helping to prevent and manage diabetes. “Two of the central areas where pharmacies and pharmacists have the greatest impact in diabetes are medication management and behavior change
June 26, 2018 by Chain Drug Review
American Diabetes Association, diabetes, Eli Lilly, Tom Hardy
Pharmacy, Supplier News

ORLANDO, Fla. — Eli Lilly’s ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi compared to Humalog. URLi is Lilly’s novel mealtime insulin currently in phase 3 development. The data was presented in
April 17, 2018 by Chain Drug Review
Boehringer Ingelheim, diabetes, Eli Lilly, Jardiance, kidney disease
Pharmacy, Supplier News

RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Co. yesterday announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical
April 5, 2018 by Chain Drug Review
diabetes, Insulins VALyou Savings Program, Michelle Carnahan, Sanofi
Pharmacy, Supplier News

BRIDGEWATER, N.J. — Sanofi’s new Insulins VALyou Savings Program will seek to help lower out-of-pocket costs for people living with diabetes who otherwise would pay full retail price for Lantus or Admelog. This includes certain uninsured patients who don’t qualify for traditional patient assistance programs, in addition to some commercially insured patients with a high